COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 282: Articles 2811-2820  | Next

Changes in the senescence profile and immune checkpoints in HIV-infected individuals after COVID-19
Crespo-Bermejo, C., Brochado-Kith, O., Grande-Garcia, S., Lara-Aguilar, V., Llamas-Adan, M., Arca-Lafuente, S., Martin-Carbonero, L., de los Santos, I., Jimenez Sousa, M. A., Resino, S., Berenguer, J., Madrid, R., Fernandez-Rodriguez, A., Briz, V.
10.1101/2024.03.12.584682 — Posted: 2024-03-13
Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice
Carolin, A., Bishop, C. R., Yan, K., Nguyen, W., Tang, B., Rawle, D. J., Suhrbier, A.
10.1101/2024.03.12.584739 — Posted: 2024-03-13
Experiences of physiotherapists working with adults living with Long COVID in Canada: a qualitative study
Kim, C., Lin, C., Wong, M., Al Hamour Al Jarad, S., Gao, A., Kaufman, N., McDuff, K., Brown, D. A., Cobbing, S., Minor, A., Chan Carusone, S., O'Brien, K. K.
10.1101/2024.03.10.24304061 — Posted: 2024-03-12
Mutational Profiling of SARS-CoV-2 PLpro in human cells reveals requirements for function, structure, and drug escape
Wu, X., Go, M., Nguyen, J. V., Kuchel, N. W., Lu, B. G. C., Lowes, K. N., Calleja, D. J., Mitchell, J. P., Lessene, G., Komander, D., Call, M. E., Call, M. J.
10.1101/2024.03.11.584210 — Posted: 2024-03-12
Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy
Datwani, S., Kalikawe, R., Waterworth, R., Mwimanzi, F. M., Liang, R., Sang, Y., Lapointe, H. R., Cheung, P. K., Omondi, F. H., Duncan, M. C., Brad, E., Speckmaier, S., Moran-Garcia, N., DeMarco, M. L., Hedgcock, M., Costiniuk, C. T., Hull, M., Harris, M., Romney, M. G., Montaner, J. S., Brumme, Z., Brockman, M. A.
10.1101/2024.03.08.24304006 — Posted: 2024-03-11
Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion
Li, P., Liu, Y., Faraone, J., Hsu, C. C., Chamblee, M., Zheng, Y.-M., Carlin, C., Bednash, J. S., Horowitz, J. C., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Jones, D., Li, J., Gumina, R. J., Liu, S.-L.
10.1101/2024.03.11.583978 — Posted: 2024-03-11
Exploring the therapeutic potential of defective interfering particles in reducing the replication of SARS-CoV-2
Locke, M., Grebennikov, D., Sazonov, I., Lopez-Garcia, M., Loguinova, M., Meyerhan, A., Bocharov, G., Molina-Paris, C.
10.1101/2024.03.11.584367 — Posted: 2024-03-11
SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1
Wang, Q., Guo, Y., Schwanz, L. T., Mellis, I. A., Sun, Y., Qu, Y., Urtecho, G., Valdez, R., Stoneman, E., Gordon, A., Wang, H. H., Liu, L., Ho, D. D.
10.1101/2024.03.10.584306 — Posted: 2024-03-11
Variant mutation in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation
Kubinski, H. C., Despres, H. W., Johnson, B. A., Schmidt, M. M., Jaffrani, S. A., Mills, M. G., Lokugamage, K., Dumas, C. M., Shirley, D. J., Estes, L. K., Pekosz, A., Crothers, J. W., Roychoudhury, P., Greninger, A. L., Jerome, K. R., Martorelli Di Genova, B., Walker, D. H., Ballif, B. A., Ladinsky, M. S., Bjorkman, P. J., Menachery, V. D., Bruce, E. A.
10.1101/2024.03.08.584120 — Posted: 2024-03-11
SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk
Korves, T., Stein, D., Walburger, D., Adamusiak, T., Roberts, S.
10.1101/2024.03.08.24303818 — Posted: 2024-03-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).